ArticleJournal of nanobiotechnology2025
Simple-synthesis VO₂ nanoparticles as robust nanozymes for synergistic antibacterial therapy and abscess repair.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Photo-responsive nanozymes: from photocatalytic mechanisms to precision therapy.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Multidrug resistant (MDR) bacterial infections, particularly those involving methicillin-resistant Staphylococcus aureus (MRSA), pose a grave threat to global population health, necessitating novel therapeutic approaches capable of circumventing existing resistance mechanisms. Biomimetic enzymes, which generate bactericidal reactive oxygen species (ROS) by mimicking natural enzyme activity, represent a highly promising solution. This study reports a straightforward one-step synthesis method for vanadium dioxide (VO₂) nanoparticles, which function as potent biomimetic enzymes exhibiting both oxidase-like and peroxidase-like activities. When combined with near-infrared laser irradiation (808 nm, 1 W/cm²) for photothermal therapy (PTT), these VO₂ nanoparticles not only mediate local hyperthermia with a photothermal conversion rate of up to 36.9%, but also significantly enhance ROS generation through biomimetic catalysis. This achieves potent synergistic effects between photothermal therapy and chemodynamic therapy (CDT). This combined therapy exhibits potent antibacterial activity against suspended methicillin-resistant Staphylococcus aureus (MRSA) and effectively disrupts preformed biofilms. Furthermore, in a subcutaneous abscess mouse model, VO₂-mediated PTT-CDT treatment efficiently eradicated bacteria, alleviated local inflammation, promoted tissue repair and angiogenesis. In summary, this readily synthesised VO₂ nanozyme system offers an efficient and translatable therapeutic strategy for tackling challenging multidrug-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.